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Abstract. Purpose: In a study to determin the effectiveness of ionizing radiation on the 
deterioration f visual acuity (VA) due to choroidal neovascularisation (CNV) the affected 
eyes of l0 patients were treated with a total dose of 24 Gy (6 Gy fractions). A special lens- 
sparing technique was used to avoid cataract development. During 30 months of follow-up the 
visual acuity (VA) and scar size (SS) of the treated eyes and fellow eyes of all 10 patients were 
evaluated. Results: After 30 months of follow-up 5 eyes showed astable VA and fluorescein 
angiogram (FA) appearance. Concerning 4 out of 5 eyes with progressive disease, the 4 eyes 
treated with radiation therapy had better VA and smaller SS as compared with the untreated 
fellow eyes with exudative AMD. Conclusions: The results uggest that 24 Gy either stabilizes 
or delays the deleterious effects of CNV on the visual acuity. Until now no late side effects 
have been observed. 
Abbreviations: AMD - Age-related macular degeneration; CNV - Choroidal neovasculariza- 
tion; DD - Disc diameter; FA - fluorescein angiogram; SS - Scar size; VA - Visual acuity. 
Introduct ion 
The exudative form of age-related macular degeneration (AMD), with the 
development of choroidal neovascularisation (CNV), is a leading cause of 
blindness in western countries. The effect of laser photocoagulation forselect- 
ed cases of subfoveal CNV is well known from the macular photocoagulation 
study (MPS) investigations [1-4]. The patient must accept an immediate and 
permanent decrease of VA after laser photocoagulation, but will have better 
VA using low-vision aids [1-3]. Only in case of a small CNV with a moderate 
or poor VA foveal ablation is recommended [4]. 
Other modalities of laserphotocoagulation including foveal sparing tech- 
niques are being proposed as alternative treatments but their definitive value 
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has not been proved [5]. Only a few patients with recent subfoveal CNV are 
suitable for laser therapy, because a large proportion (87%) of patients have 
an occult type of CNV at presentation [6]. Alternative forms of therapy for 
CNV are proposed, like submacular surgery, Interferon therapy, ICG-guided 
laser therapy and Thalidomide therapy but none of these new therapies seems 
to be valuable [7]. 
Patients with unilateral age-related xudative maculopathy developed neo- 
vascular membranes in the fellow eye in 31% of cases after 4 years of follow- 
up, and in general patients with exudative disease in one eye develop CNV 
in the fellow eye at a rate of about 10% per year [8]. The hypothesis that 
ionizing radiation may prevent endothelial cell proliferation and/or induce 
aberrant vessel obliteration and influences macrophages depended growth 
factors and/or egulatory genes, in case of CNV, is under investigation [7]. 
After the first report concerning the effect of radiation therapy on subfoveal 
CNV in 1992, several other eports were published [9-14]. We are now able 
to present he results after 30 months of follow-up concerning ten patients 
treated with radiation therapy with a total dose of 24 Gy (6 Gy fractions). 
We decided to do a longer follow-up in this group of patients because 
initially they showed the best results after 12 months post-irradiation i  our 
pilot study [11,13]. 
Materials and methods 
This study was performed with permission of the institutional ethical commit- 
tee for clinical experiments. The early results of this group of patients were 
previously published [11,13]. Ten patients with subfoveal CNV and recent 
decrease of VA were treated with a total dose of 24 Gy in 4 fractions of 6 Gy 
in the macular area. The time between two consecutive fractions was 1 week 
and the overall treatment time was 3 weeks. The dose was delivered by two 
1 square cm 16 MV photon beams. The two photon beams diverge 30 degree 
from the eye axis and cross the eye axis in the macular area. By this technique 
the lens will receive less than 20% of the dose. 
All patients underwent a complete ophthalmic examination of both eyes, 
including FA, before treatment and 3, 12, 18 and 30 months post-treatment. 
The early, mid and late venous phase of the pre- and post-treatment a giograms 
were analysed using an over-projection sheet for measuring the size of the 
membrane (in disc diameters =DD) and the leakage of fluorescein i  the late 
phase. When there was an increase in size of the CNV in the early phase 
and/or an increase in late phase leakage the CNV membrane was consid- 
ered to be progressive. When no change between the pre- and post-treatment 
angiograms was seen, the CNV was considered as stable. Any CNV with a 
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classic component but partial occult (including subretinal bloud and/or fluid 
or late undetermined leakage) was classified as occult ype of CNV. 
A decrease in VA was defined as a drop of 2 or more lines at the Snellen 
test. A stable VA was defined as an increase or decrease within 2 lines from 
initial best corrected VA. After 30 months of follow-up the VA and FA of the 
treated eyes and fellow eyes of all 10 patients were documented. 
Results 
The patients treated with a total dose of 24 Gy (6 Gy fractions) showed the 
following characteristics (Tables 1 and 2): 
Patient 1: Male, 72 years. He presented with a classic type of CNV in the 
right eye and an initial VA of 0.3 (Figure 1A red free, Figure 1B early phase, 
Figure 1C late phase OD before treatment). After 30 months of followup the 
VA was 0.2 and the central SS was 1 DD (Figure 2A red free, Figure 2B early 
phase, Figure 2C late phase OD after treatment). His fellow left eye showed 
drusen and a VA of 1.0. 
Patient 2: Female, 71 years. This patient initially had a VA af 0.2 and an 
occult type of CNV. After 30 months the VA dropped one line to 0.1 and the 
FA appearance of the CNV remained stable with a scar size of 2 DD. Her 
fellow eye with a scar of 2 DD had a VA of 0.4. 
Patient 3: Female, 80 years. This patient showed adrop in VA from 0.08 to 
1/60 within 3 months after adiation therapy for occult CNV. After 30 months 
of follow-up her VA in the study eye is 1/60 with a SS of 6 DD. Her fellow eye 
already had disciform scarring for more than one year without laser treatment 
at presentation, with a SS of 12 DD. After 30 months of follow-up the SS in 
the fellow eye stabilized and the VA remained 2/300. 
Patient 4: Female, 74 years. This patient presented with a classic CNV 
(OD) and an initial VA of 0.25 (Figure 3A red free, Figure 3B early phase, 
Figure 3C late phase OD before treatment). A drop in VA occurred after 18 
months post-radiation treatment and she ended up with a VA of 0.1 and a SS 
of 2 DD after 30 months (Figure 4A red free, Figure 4B early phase, Figure 
4C late phase OD after treatment). The fellow left eye showed untreated 
disciform scarfing present for more than one year at presentation (Figure 5A 
red free, Figure 5B late phase OS) and with a stable SS of 6 DD and a VA of 
2/60 after 30 months of follow-up (Figure 6A red free, Figure 6B late phase 
OS). 
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Figure I. Patient 1 with a classic type of CNV of the right eye and a VA of 0.3 at presentation 
before radiation treatment. Figure 1A. Red free picture of the FA. 
Figure lB. Early phase of the FA. 
65 
Figure 1C. Late phase of the FA. 
Patient 5: Female, 83 years. The left eye with a classic CNV and an initial 
VA of 0.2 showed astable angiogram with a SS of 2 DD after 30 months. The 
VA decreased to0.125 after 30 months post-treatment. The fellow eye has a 
VA of 0.8 and drusen in the macular area. 
Patient 6: Male, 72 years. This patient presented with a classic CNV with 
an initial VA of 0.2. A decrease in VA to 0.1 after 6 months and to 1/60 after 
12 months post-treatment occurred. The SS of 1 DD at presentation e larged 
to 4 DD at 30 months of follow-up. The fellow right eye still has a VA of 0.8 
and has some pigmetary changes in the macular area. 
Patient 7: Male, 85 years. Between 12 and 18 months after treatment for 
occult CNV, the VA declined from 0.16 to 2/60 and after 30 months the VA 
is 2/60 with a SS of 5 DD. The fellow eye with a VA of 1/60 had disciform 
scarring, without previous laser treatment, at presentation with a SS of 6 DD. 
Patient 8: Male 76years. The left eye with classic CNV and an initial VA of 
0.5 showed adecrease inVA to 0.2 after 12 months and to 0.08 after 30 months 
of follow-up with an increase in SS from 1 DD to 3 DD. The fellow eye with 
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Figure 2. Patient 1 with a classic CNV of the right eye and a VA of 0.2, 30 months after 
radiation treatment. The late phase (Figure 2C) shows a central SS of I DD and the late phase 
leakage is less compared withthe pre-treatment angiogram (Figure IC) Figure 2A. Red free 
picture of the FA. 
a VA of 1/60 and a scar size of 4 DD at presentation remained stable during 
30 months of follow-up. This eye was not treated with laserphotocoagulation. 
Patient 9: Male 77 years. The right eye presented with a classic CNV and 
a VA of 0.16. At the end of the follow-up period the VA increased to 0.25 and 
the FA remained stable. The fellow eye with some drusen had a stable VA of 
0.8. 
Patient I O: Female 73 years. This patient with a classic CNV had a stable 
VA of 0.3 during the follow-up period, with a SS size of 1 DD. The fellow 
eye with a VA of 0.8 did not show any change. 
Conclusions 
Thirty months after radiotherapy, with a total dose of 24 Gy, 5 out of 10 
patients have a stable VA without progression of the CNV on FA (Table 1). 
Patient 1, 5, 9 and 10 presented with a classic CNV, while patient 2 had an 
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Figure 2B. Early phase of the FA. 
Figure 2C. Late phase of the FA. 
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Figure 3. Patient 4 with a classic type of CNV of type right eye and a VA of 0.25 at presentation 
before radiation treatment. Figure 3A. Red free picture of the FA. 
Figure 3B. Early phase of the FA with well-demarcated hyperfluorescence. 
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Figure 3C. Late phase of the FA with leakage. 
Table 1. Patients (n-5) with stable visual 
acuity (VA) and scar size (SS) on fluorescein 
angiography 30 months after radiation thera- 
py with a total dose of 24 Gy (6 Gy fractions) 
compared with t e untreated fellow eye 
Patient 
No 
Study eye Fellow eye 
VA SS VA SS 
1. 0.2 1 DD 1.0 drusen 
2. 0.1 2 DD 0.4 2 DD 
5. 0.125 2 DD 0.8 drusen 
9. 0.25 2 DD 0.8 drusen 
10. 0.3 1 DD 0.8 drusen 
occult CNV. The VA initially was better than 0.1 and remained stable in all 
cases at 30 months after radiotherapy. 
The other 5 patients had progressive disease with a decrease in VA and an 
increase in SS despite radiation therapy (Table 2). Patient 3, 6 and 7 ended 
up with a VA of finger counting at 1 or 2 meter, while patient 4 and 6 had a 
VA of 0.1 and 0.08 respectively after 30 months. 
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Figure 4. Patient 4 with a classic type of CNV of the fight eye and a VA of 0.1, 30 months 
after radiation therapy. The late phase (Figure 4C) shows a central SS of 2 DD. Figure 4A. 
Red free picture of the FA. 
Table 2. Patients (n=5) with deterioration of 
visual acuity (VA) and scar size (SS) on fluo- 
rescein angiography 30 months after adiation 
therapy with a total dose of 24 Gy (6 Gy frac- 
tions) compared with the untreated fellow eye 
Patient 
No 
Study eye Fellow eye 
VA SS VA SS 
3. 1/60 6 DD 2/300 12 DD 
4. 0.1 2 DD 3/60 6 DD 
6. 1/60 4 DD 0.8 drusen 
7. 2/60 5 DD 1/60 6 DD 
8. 0/08 3 DD 1/60 4 DD 
Four  (patient 3, 4, 7, 8) o f  the the 5 patients with progressive disease, 
had untreated isciform scarring in the fel low eye at presentation. The 4 eyes 
treated with radiation therapy had better VA and smaller SS compared with the 
untreated fellow eyes after 30 months of  fo l low-up (Table 2). Until now we 
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Figure 4B. Early phase ofthe FA. 
Figure 4C. Late phase of the FA. 
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Figure 5. Patient 4 with a disciform lesion of the untreated left eye at pr sentation. Figure 5A. 
Red free picture of the FA. 
did not see any severe side-effects of this radiation therapy such as radiation 
retinopathy or dry eyes. Slight changes in lensopacification, however, can not 
be ruled out. 
Discussion 
In exudative AMD new capillaries proliferate under the retinal pigment 
epithelium and/or between the retinal pigment epithelium and the retina after 
they have broken through Bruch's membrane. They leak blood, lipoproteins 
and subretinal f uid in the active phase. Over a period of months fibrous tissue 
appaers with the development of a fibrovascular disciform scar, with sec- 
ondary destruction of the overlying photoreceptors and the remaining retinal 
pigment epithelium. According to Bird there are no well formulated concepts 
conceming the mechanism by which neovascularisation is induced. Maybe 
macrophages cause vasoproliferation by producing rowth factors [15]. Fin- 
ger et al. concluded after reviewing the literature that possibly radiotherapy 
indirectly effect genes resulting in growth arrest and / or apoptosis [14]. 
The Belfast study group postulated that radiotherapy acts to minimise size 
and intensity of the disciform response, through arresting the proliferation 
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Figure 5B. Late phase of the FA. Late phase ofthe FA of the untreated left eye with disciform 
scarring and a stable SS of 6 DD after 30 months of follow-up. There is clearly a difference 
in scar size between the treated right eye (Figure 4C) of pati nt 4 and the untreated left eye 
(Figure 5B). Although the patient had slight myopic correction in both eyes (S-2.0), she also 
had age-related peripapillary atrophy. 
of endothelial cells resulting in mitotic cell death and through its attenuating 
effects on the inflammatory response resulting in a reduced disciform scar 
[12]. Their results concerning radiotherapy for exudative AMD are encour- 
aging, because the VA was significantly better and the SS was smaller in 11 
eyes treated with radiotherapy, compared with the untreated fellow eyes with 
disciform scarring after a mean follow-up of 28 months [12]. 
After reviewing the literature they concluded that concordance in scar 
size between the eyes of untreated patients was found to be highest when the 
duration of the disease was at least 12 months in the second eye to be affected. 
This implies that the appearance of the fibrovascular disciform scar does not 
change substantially after 12 months from initial presentation [12]. 
The natural course of the visual acuity in patients with classic or occult 
CNV is known from many studies [1-4]. The VA of eyes with untreated 
subfoveal CNrV with an initial VA of 0.1 or better, will decrease to 0.08 or 
worse in 44% of eyes after 3 months of follow-up and in 80.5% of eyes after 
24 months of follow-up. 
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When compared to the natural course of the disease (80.5% of eyes dete- 
riorate to a VA of 0.08 or worse within 24 months) radiation therapy with a 
dose of 24 Gy seems to have a beneficial effect on the VA (3 of 10 eyes had 
a VA of 0.08 or worse within 30 months ). 
Although 5 eyes showed progresssive disease after radiation therapy, we 
noticed in 4 of them a better VA and smaller SS after 30 months, when 
compared with the untreated fellow eyes with exudative AMD. These results 
confirm the results of the Belfast study group [12]. 
Radiation may have some negative side effects on the eye when doses are 
given beyond tolerance levels. The lens is a relatively radiosensitive structure 
and opacification will develop when doses exceed 6 - 12 Gy. 
In this study the radiation was applied in such a way that the lens was more 
or less spared. Until now there are no indications that there is an increased 
incidence of cataract in the treated eyes. More severe side effects such as 
radiation retinopathy or radiation optic neuropathy are rare after doses of 
46.5 Gy and 55 Gy (2.0 Gy fractions) respectively [16]. Four fractions of 6 
Gy, given in 3 weeks, is more or less biologically equivalent to 50 Gy given in 
25 daily fractions of 2 Gy. The incidence of radiation damage after 24 Gy (6 
Gy fractions) is expected to be very low and quite safe [16,17]. As expected 
no cases of radiation retinopathy are observed until now. 
In conclusion, after a substantial period of follow-up (30 months), 7 of 10 
patients treated with a total dose of 24 Gy (6 Gy fractions) in the macular 
area, maintained a VA of 0.08 or better while, concerning the natural course 
data, 20% was expected. 
This data, including the reduction in scar area after radiation treatment, 
suggest a beneficial effect of radiation therapy in subfoveal exudative age- 
related disease. 
The overall conclusion during the meeting of the American Academy of 
Ophthalmology inOctober 1995 was that there is a strong theoretical basis for 
this therapy but that a definite answer has to come from long-term prospective 
randomized controlled trials. In several centers over the world, including in 
the Netherlands, these trials are under way. 
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